Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini-CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information:
Caravan Biologix, Inc.:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri COP28 LinkedIn Livestream Featuring: City of Sydney, Australia11.12.2023 18:01:00 CET | Press release
Esri: Date: Thursday, December 14, 2023 Time: 3:00 p.m. PST/6:00 p.m. EST Register Here Moderator: Brett Dixon, Esri Asia Pacific Spatial Industry Specialist & Business Leader Panelists: Matt Sund, City of Sydney Spatial Information Services Manager Karen Sweeney, City of Sydney Urban Forestry Manager Esri, a world leader in Geographic Information Systems (GIS) software solutions, is hosting a LinkedIn livestream on Thurs., December 14 featuring the City of Sydney, Australia. During the livestream, leaders from the City of Sydney will discuss their novel approach to advancing tree equity, no matter where their citizens live, along with increasing biodiversity in trees and the wildlife that rely on them. Rapid growth in greater Sydney has resulted in the loss of biodiversity and green, shady places. In the past decade, more than half of greater Sydney’s neighborhoods have lost urban forest cover, as experts warn that suburbs lacking sufficient tree cover may become unlivable. Now, the s
Obsidian Security Recognized as Strong Performer by Independent Research Firm11.12.2023 17:18:00 CET | Press release
We’re thrilled to share that Obsidian Security has been named a Strong Performer while receiving the highest scores possible across five criteria in The Forrester Wave™: SaaS Security Posture Management, Q4 2023 – the first Forrester Wave(™) report to be released in the SaaS Security and Posture Management (SSPM) category. Forrestergave the Obsidian Posture Management module the highest scores possible in the configuration drift detection and SaaS app configuration templates criteria. Additionally, the Obsidian Integration Risk Management module received the highest possible score in the connected apps criterion. Forrester also gave Obsidian the highest score possible in the IAM administration criterion supported by Obsidian Advanced Threat Mitigation module. The Forrester report recognized Obsidian as a vendor providing “a single, modular platform” for SaaS Security and Posture Management. The Obsidian Advanced Threat Mitigation module covers authentication monitoring and remediation,
Transition Industries LLC and Macquarie Group Announce Marketing Agreement for Low Carbon Methanol Project in Sinaloa, Mexico11.12.2023 15:13:00 CET | Press release
Transition Industries LLC announced at COP 28 that it has entered into a Master Services and Marketing Agreement (MSMA) with Macquarie Commodities Trading, an affiliate of Macquarie Group’s Commodities and Global Markets business (“Macquarie” / “CGM”), for its Pacifico Mexinol project, a 6,145 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico (“Pacifico Mexinol” or the “Project”). When it commences operations, Pacifico Mexinol is expected to be one of the largest single low carbon chemicals facilities in the world - producing approximately 300,000 MT of green methanol from captured carbon and green hydrogen and 1.8 million MT of blue methanol per year from natural gas with carbon capture. Under the terms of the MSMA, Macquarie is responsible for marketing all the production from Pacifico Mexinol to customers on a global basis in accordance with methanol offtake agreements, the provisioning of financial hedging services as required by the Project, and supporting
New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life11.12.2023 15:00:00 CET | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analysed baseline data collected prior to initiation of study treatment and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS). “CTCL is a chronic, life-long condition. Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors. “The data provide new insights into the burdens of living with CTC
Battery Manufacturer Hithium Opens New 28 GWh Intelligent Production Plant11.12.2023 15:00:00 CET | Press release
Stationary energy storage expert Hithium will release 28 GWh planned production capacity successively at first stage of Phase 1 of its new base in Chongqing, China. The new plant is designed in line with "Intelligent Manufacturing 4.0" standards, including a 26% increase in automation over the typical "Intelligent Manufacturing 3.0" production system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231211098435/en/ Hithium Chongqing production plant (Photo: Business Wire) Hithium’s automation gains at Chongqing have resulted in an overall efficiency jump of 30%, as well as cost reductions amounting to a quarter of production overhead, delivering a significant lead in manufacturing competitiveness. Built with an investment of RMB13 billion ($1.8 billion), the site covers 800,000 m2 and is located in the Tongliang high-tech zone. The new capacity aims at helping to meet global demand for what is expected to be 720GW of energy s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom